DexCom, Inc. $DXCM Shares Bought by Freemont Management S.A.

Freemont Management S.A. increased its position in DexCom, Inc. (NASDAQ:DXCM) by 196.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 17,800 shares of the medical device company’s stock after acquiring an additional 11,800 shares during the period. Freemont Management S.A.’s holdings in DexCom were worth $1,181,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Trust Co. of Vermont grew its holdings in DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after acquiring an additional 145 shares during the period. CVA Family Office LLC lifted its holdings in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the last quarter. IFP Advisors Inc lifted its holdings in DexCom by 24.7% in the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after acquiring an additional 178 shares during the last quarter. Personal CFO Solutions LLC lifted its holdings in DexCom by 5.0% in the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after acquiring an additional 185 shares during the last quarter. Finally, Inspire Advisors LLC lifted its holdings in DexCom by 2.5% in the 3rd quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock valued at $533,000 after acquiring an additional 194 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $58.57 on Thursday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The firm has a market capitalization of $22.60 billion, a PE ratio of 25.03, a P/E/G ratio of 1.05 and a beta of 1.40. The firm has a 50-day moving average of $63.99 and a two-hundred day moving average of $66.01.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the firm earned $0.32 earnings per share. The business’s quarterly revenue was up 15.0% on a year-over-year basis. On average, analysts forecast that DexCom, Inc. will post 2.56 earnings per share for the current year.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total transaction of $107,168.00. Following the completion of the sale, the executive vice president directly owned 111,204 shares of the company’s stock, valued at approximately $7,010,300.16. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.28% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the subject of a number of research analyst reports. Sanford C. Bernstein set a $77.00 price target on shares of DexCom in a report on Friday, May 1st. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target for the company in a report on Tuesday, March 24th. Weiss Ratings raised shares of DexCom from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Mizuho set a $75.00 price target on shares of DexCom in a report on Friday, May 1st. Finally, Citigroup reissued a “buy” rating and issued a $79.00 price target (down from $84.00) on shares of DexCom in a report on Monday, May 4th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $83.22.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.